Viz.ai has partnered with Alnylam Pharmaceuticals to develop an AI-based care pathway for cardiac amyloidosis.
The Viz Cardiac Amyloidosis Care Pathway is designed to accelerate early identification and standardize diagnostic evaluation of the condition, Viz.ai said.
Cardiac amyloidosis is associated with misfolded proteins deposited in the heart muscle and can lead to heart failure and poor outcomes if left untreated, the company noted.
Using AI to automatically analyze standard echocardiograms, the program will identify patients with symptoms of cardiac amyloidosis, and enable coordinated confirmatory testing, referral, and follow-up across cardiology and heart failure teams, the company explained.
The pilot program will launch with a multisite study to evaluate clinical workflow integration and generate real-world evidence on its impact on diagnosis, time to treatment, and care coordination, the company said.
